Atossa Therapeutics and Insilico Medicine Identify (Z)-Endoxifen as Potential Glioblastoma Treatment in AI-Driven Study
Atossa Therapeutics Inc., in collaboration with Insilico Medicine, has published a study identifying (Z)-endoxifen as a potential treatment for glioblastoma multiforme (GBM) using AI technology. The study, published in Nature Scientific Reports, highlights GBM as a promising candidate for further research. While no clinical trials have been announced, the findings suggest potential future therapeutic programs.
Atossa Therapeutics Inc., in collaboration with Insilico Medicine, has announced the publication of a joint study evaluating (Z)-endoxifen as a potential therapeutic candidate for glioblastoma multiforme (GBM). The results of the study, which utilized Insilico’s AI-powered PandaOmics platform to systematically explore new oncology indications for endoxifen, have been published in Nature Scientific Reports. The study identified GBM as a top candidate for further investigation of (Z)-endoxifen, an active metabolite of tamoxifen with known activity in endocrine-resistant breast cancer. The announcement did not specify the initiation of a clinical trial, but highlighted the publication of these preclinical findings and the potential for future therapeutic programs. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atossa Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: SF31216) on December 02, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
